Suppr超能文献

一种新型普萘洛尔/氢氯噻嗪片剂组合的生物制药特性。

Biopharmaceutical characteristics of a new propranolol/hydrochlorothiazide tablet combination.

作者信息

Kraml M, Dubuc J, Dvornik D, Patterson-Kreuscher S, Perdue H, Lee T Y, Mullane J

出版信息

Biopharm Drug Dispos. 1982 Jan-Mar;3(1):55-65. doi: 10.1002/bdd.2510030108.

Abstract

Experiments have been carried out in dogs and man to determine the effect of hydrochlorothiazide (HCT) on the pharmacokinetics of propranolol and to evaluate the bioavailability of two dosage forms containing both propranolol and HCT (40/25 and 80/25 mg, respectively). In adult male beagles, 50 mg of HCT had no apparent effect on AUC, Cmax, Tmax, and T1/2 of propranolol administered concurrently. In man, INDERIDE (40/25 mg) and INDERIDE (80/25 mg) were shown to be similar in bioavailability to the reference formulations, i.e. the same amount of drugs administered as the separate tablets of INDERAL plus HYDRODIURIL.

摘要

已在犬类和人体中开展实验,以确定氢氯噻嗪(HCT)对普萘洛尔药代动力学的影响,并评估两种含普萘洛尔和HCT(分别为40/25和80/25毫克)剂型的生物利用度。在成年雄性比格犬中,50毫克HCT对同时给予的普萘洛尔的AUC、Cmax、Tmax和T1/2无明显影响。在人体中,显示英得立(40/25毫克)和英得立(80/25毫克)的生物利用度与参比制剂相似,即给予与心得安加氢氯噻嗪单独片剂相同剂量的药物。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验